# US 2004/0019181 A1 · Antimicrobial cationic peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0019181 A1
- Document ID: US20040019181A1
- Status: Published application
- Kind: A1
- Application number: 10/403,104
- Filed: 2003-03-28
- Published: 2004-01-29
- Earliest claimed: 1995-08-23
- Assignees: The University of British Columbia
- Inventors: Timothy J. Falla; Robert E.W. Hancock; Monisha Gough
- Web page: https://patentgrep.com/patent/US20040019181A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X1X1PX2X3X2P(X2X2P)nX2X3(X5)0; (SEQ ID NO: 23) X1X1PX2X3X4(X5)rPX2X3X3; (SEQ ID NO: 24) X1X1X3(PW)uX3X2X5X2X2X5X2(X5)0; and (SEQ ID NO: 25) X1X1X3X3X2P(X2X2P)nX2(X5)m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine X3 represents Arginine or Lysine; X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.

## Claims

### Claim 1

An isolated cationic peptide having antimicrobial activity and an amino acid sequence selected from the group consisting of:
X1X1PX2X3X2P(X2X2P)nX2X3(X5)0; (SEQ ID NO: 23) X1X1PX2X3X4(X5)rPX2X3X3; (SEQ ID NO: 24) X1X1X3(PW)uX3X2X5X2X2X5X2(X5)0; and (SEQ ID NO: 25) X1X1X3X3X2P(X2X2P)nX2(X5)m; (SEQ ID NO: 26)
wherein:
m is 1 to 5;
n is 1 or 2;
o is 2 to 5;
r is 0 to 8;
u is 0 or 1;
X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine;
X2 represents Tryptophan or Phenylalanine;
X3 represents Arginine or Lysine;
X4 represents Tryptophan or Lysine; and
X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline.

### Claim 2 (depends on 1)

A peptide of claim 1 having an amino acid sequence selected from the group consisting of:
ILKKWPWWPWRRK (SEQ ID NO: 1);
ILKPWKWPWWPWRRKK (SEQ ID NO: 2);
ILKPWKWPWWPWRR (SEQ ID NO: 3);
ILPWKKWPWWRWRR (SEQ ID NO: 4);
ILKKWPWWPWRR (SEQ ID NO: 5);
ILPWKWPWWPWRKWR (SEQ ID NO: 6);
ILPWKWPWWPWRRWR (SEQ ID NO: 7);
ILPWKWPWWPWKKWK (SEQ ID NO: 8);
ILPWKWPWRR (SEQ ID NO: 10);
ILPWKWPWWPWWPWRR (SEQ ID NO: 11);
ILPWKWPWWPWWKKPWRR (SEQ ID NO: 12);
IKWPWYVWL (SEQ ID NO: 20)
ILPWKWFFPPWPWRR (SEQ ID NO: 21);
ILPWKWPPWPPWPWRR (SEQ ID NO: 22)
ILKKFPFFPFRRK (SEQ ID NO: 28); and
FFKKFPFFPFRRK (SEQ ID NO: 36).

### Claim 3 (depends on 1)

A peptide of claim 1 having an amino acid sequence selected from the group consisting of:
ILKKWPWWPWKRR (SEQ ID NO: 17);
ILKKWPWWRWRR (SEQ ID NO: 27);
ILKKFPFFPFKKK (SEQ ID NO: 29);
ILKKWAWWPWRRK (SEQ ID NO: 30);
ILKKWPWWAWRRK (SEQ ID NO: 31);
ILKKWPWWPWKKK (SEQ ID NO: 32);
ILRRWPWWPWRRR (SEQ ID NO: 33);
WWKKWPWWPWRRK (SEQ ID NO: 34);
FFKKWPWWPWRRK (SEQ ID NO: 35);
FFKKFPFFPFKKK (SEQ ID NO: 36);
ILKKWPWWPWWPWRRK (SEQ ID NO: 38);
ILKKWPWWPWRWWRR (SEQ ID NO: 39);
ILKKWPWWPWRRWWK (SEQ ID NO: 40);
ILKKWPWWPWPPRRK (SEQ ID NO: 41); and
ILKKWPWWPWPPFFRRK (SEQ ID NO: 42).

### Claim 4

An isolated cationic peptide having antimicrobial activity and an amino acid sequence selected from the group consisting of:
PWKWPWWPWRR (SEQ ID NO: 9);
ILPWICPWRPSKAN (SEQ ID NO: 13);
IVPWKWTLWPWRR (SEQ ID NO: 14); and
TLPCLWPWWPWSI (SEQ ID NO: 15).

### Claim 5 (depends on 1)

An isolated nucleic acid that encodes a peptide of claim 1.

### Claim 6 (depends on 4)

An isolated nucleic acid that encodes a peptide of claim 4.

### Claim 7

A method for inhibiting the growth of a bacterium or yeast comprising contacting the bacterium or yeast with an inhibiting effective amount of a peptide having an amino acid sequence selected from the group consisting of:
X1X1PX2X3X2P(X2X2P)nX2X3(X5)0; (SEQ ID NO: 23) X1X1PX2X3X4(X5)rPX2X3X3; (SEQ ID NO: 24) X1X1X3(PW)uX3X2X5X2X2X5X2(X5)0; and (SEQ ID NO: 25) X1X1X3X3X2P(X2X2P)nX2(X5)m; (SEQ ID NO: 26)
wherein:
m is 1 to 5;
n is 1 or 2;
o is 2 to 5;
r is 0 to 8;
u is 0 or 1;
X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine;
X2 represents Tryptophan or Phenylalanine;
X3 represents Arginine or Lysine;
X4 represents Tryptophan or Lysine; and
X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline.

### Claim 8 (depends on 7)

The method of claim 7, wherein the peptide has an amino acid sequence selected from the group consisting of:
ILKKWPWWPWRRK (SEQ ID NO: 1);
ILKPWKWPWWPWRRKK (SEQ ID NO: 2);
ILKPWKWPWWPWRR (SEQ ID NO: 3);
ILPWKKWPWWRWRR (SEQ ID NO: 4);
ILKKWPWWPWRR (SEQ ID NO: 5);
ILPWKWPWWPWRKWR (SEQ ID NO: 6);
ILPWKWPWWPWRRWR (SEQ ID NO: 7);
ILPWKWPWWPWKKWK (SEQ ID NO: 8);
ILPWKWPWRR (SEQ ID NO: 10);
ILPWKWPWWPWWPWRR (SEQ ID NO: 11);
ILPWKWPWWPWWKKPWRR (SEQ ID NO: 12);
ILKKWPWWPWKWKK (SEQ ID NO: 18);
ILPWKWFFPPWPWRR (SEQ ID NO: 21);
ILPWKWPPWPPWPWRR (SEQ ID NO: 22);
ILKKFPFFPPRRK (SEQ ID NO: 28); and
FFKKFPFFPFRRK (SEQ ID NO: 36).

### Claim 9 (depends on 7)

The method of claim 7, wherein the peptide has an amino acid sequence selected from the group consisting of:
ILKKWPWWPWKRR (SEQ ID NO: 17);
ILKKWPWWRWRR (SEQ ID NO: 27);
ILKKFPFFPFKKK (SEQ ID NO: 29);
ILKKWAWWPWRRK (SEQ ID NO: 30);
ILKKWPWWAWRRK (SEQ ID NO: 31);
ILKKWPWWPWKKK (SEQ ID NO: 32);
ILRRWPWWPWRRR (SEQ ID NO: 33);
WWKKWPWWPWRRK (SEQ ID NO: 34);
FFKKWPWWPWRRK (SEQ ID NO: 35);
FFKKFPFFPFKKK (SEQ ID NO: 37);
ILKKWPWWPWWPWRRK (SEQ ID NO: 38);
ILKKWPWWPWRWWRR (SEQ ID NO: 39);
ILKKWPWWPWRRWWK (SEQ ID NO: 40);
ILKKWPWWPWPPRRK (SEQ ID NO: 41); and
ILKKWPWWPWPPFFRRK (SEQ ID NO: 42).

### Claim 10 (depends on 7)

The method of claim 7, wherein the bacterium is gram positive.

### Claim 11 (depends on 10)

The method of claim 10, wherein the bacterium is Staphylococcus aureus or S. epidermidis.

### Claim 12 (depends on 7)

The method of claim 7, wherein the bacterium is gram negative.

### Claim 13 (depends on 12)

The method of claim 12, wherein the bacterium is selected from the group consisting of E. coli P. aeruginosa, and S. typhimurium.

### Claim 14 (depends on 7)

The method of claim 7, further comprising contacting the bacterium or yeast with at least one antibiotic.

### Claim 15 (depends on 14)

The method of claim 14, wherein the antibiotic is selected from the group consisting of a β-lactam, novobiocin, and polymyxin B.

### Claim 16 (depends on 7)

The method of claim 7, wherein the yeast is Candida albicans.

### Claim 17

A method for inhibiting the growth of a bacterium or yeast comprising contacting the bacterium or yeast with an inhibiting effective amount of a peptide having an amino acid sequence selected from the group consisting of:
PWKWPWWPWRR (SEQ ID NO: 9);
ILPWICPWRPSKAN (SEQ ID NO: 13);
IVPWKWTLWPWRR (SEQ ID NO: 14); and
TLPCLWPWWPWSI (SEQ ID NO: 15).

### Claim 18 (depends on 17)

The method of claim 17, wherein the bacterium is gram positive.

### Claim 19 (depends on 18)

The method of claim 18, wherein the bacterium is Staphylococcus aureus or S. epidermidis.

### Claim 20 (depends on 17)

The method of claim 17, wherein the bacterium is gram negative.

### Claim 21 (depends on 20)

The method of claim 20, wherein the bacterium is selected from the group consisting of E. coli, P. aeruginosa, and S. typhimurium.

### Claim 22 (depends on 17)

The method of claim 17, further comprising contacting the bacterium or yeast with at least one antibiotic.

### Claim 23 (depends on 22)

The method of claim 22, wherein the antibiotic is selected from the group consisting of a β-lactam, novobiocin, and polymyxin B.

### Claim 24 (depends on 17)

The method of claim 17, wherein the yeast is Candida albicans.

### Claim 25

A method for inhibiting an endotoxemia or sepsis associated disorder in a subject having or at risk of having such a disorder, comprising administering to the subject a therapeutically effective amount of a cationic peptide having antimicrobial activity and an amino acid sequence selected from the group consisting of:
X1X1PX2X3X2P(X2X2P)nX2X3(X5)0; (SEQ ID NO: 23) X1X1PX2X3X4(X5)rPX2X3X3; (SEQ ID NO: 24) X1X1X3(PW)uX3X2X5X2X2X5X2(X5)0; and (SEQ ID NO: 25) X1X1X3X3X2P(X2X2P)nX2(X5)m (SEQ ID NO: 26)
wherein:
m is 1 to 5;
n is 1 or 2;
o is 2 to 5;
r is 0 to 8;
u is 0 or 1;
X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine;
X2 represents Tryptophan or Phenylalanine;
X3 represents Arginine or Lysine;
X4 represents Tryptophan or Lysine; and
X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline.

### Claim 26 (depends on 25)

The method of claim 25, wherein the peptide has an amino acid sequence selected from the group consisting of:
ILKKWPWWPWRRK (SEQ ID NO: 1);
ILKPWKWPWWPWRRKK (SEQ ID NO: 2);
ILKPWKWPWWPWRR (SEQ ID NO: 3);
ILPWKKWPWWRWRR (SEQ ID NO: 4);
ILKKWPWWPWRR (SEQ ID NO: 5);
ILPWKWPWWPWRKWR (SEQ ID NO: 6);
ILPWKWPWWPWRRWR (SEQ ID NO: 7);
ILPWKWPWWPWKKWK (SEQ ID NO: 8);
ILPWKWPWRR (SEQ ID NO: 10);
ILPWKWPWWPWWPWRR (SEQ ID NO: 11);
ILPWKWPWWPWWKKPWRR (SEQ ID NO: 12);
ILKKWPWWPWKWKK (SEQ ID NO: 18);
ILPWKWFFPPWPWRR (SEQ ID NO: 21);
ILPWKWPPWPPWPWRR (SEQ ID NO: 22)
ILKKFPFFPFRRK (SEQ ID NO: 28); and
FFKKFPFFPFRRK (SEQ ID NO: 36).

### Claim 27 (depends on 25)

The method of claim 25, wherein the peptide has an amino acid sequence selected from the group consisting of:
ILKKWPWWPWKRR (SEQ ID NO: 17);
ILKKWPWWRWRR (SEQ ID NO: 27);
ILKKFPFFPFKKK (SEQ ID NO: 29);
ILKKWAWWPWRRK (SEQ ID NO: 30);
ILKKWPWWAWRRK (SEQ ID NO: 31);
ILKKWPWWPWKKK (SEQ ID NO: 32);
ILRRWPWWPWRRR (SEQ ID NO: 33);
WWKKWPWWPWRRK (SEQ ID NO: 34);
FFKKWPWWPWRRK (SEQ ID NO: 35);
FFKKFPFFPFKKK (SEQ ID NO: 37);
ILKKWPWWPWWPWRRK (SEQ ID NO: 38);
ILKKWPWWPWRWWRR (SEQ ID NO: 39);
ILKKWPWWPWRRWWK (SEQ ID NO: 40);
ILKKWPWWPWPPRRK (SEQ ID NO: 41); and
ILKKWPWWPWPPFFRRK (SEQ ID NO: 42).

### Claim 28 (depends on 25)

The method of claim 25, wherein the disorder is septic shock.

### Claim 29

A method for inhibiting an endotoxemia or sepsis associated disorder in a subject having or at risk of having such a disorder, comprising administering to the subject a therapeutically effective amount of a cationic peptide having antimicrobial activity and an amino acid sequence selected from the group consisting of:
PWKWPWWPWRR (SEQ ID NO: 9);
ILPWICPWRPSKAN (SEQ ID NO: 13);
IVPWKWTLWPWRR (SEQ ID NO: 14);
TLPCLWPWWPWSI (SEQ ID NO: 15);
ILPWKWPWYVRR (SEQ ID NO: 19); and
IKWPWYVWL (SEQ ID NO: 20).

### Claim 30 (depends on 29)

The method of claim 29, wherein the disorder is septic shock.

### Claim 31

A method for producing a cationic peptide variant having antimicrobial activity comprising:
identifying the amino acid sequence of a reference cationic peptide having antimicrobial activity;
creating an expression library encoding cationic peptide variants of the reference peptide, wherein a plurality of the variants each contain at least one substitution of an amino acid of the identified amino acid sequence;
expressing the library in a host cell, thereby producing a plurality of clones; and
isolating a clone that produces a cationic peptide variant having antimicrobial activity.

### Claim 32 (depends on 31)

A cationic peptide variant produced by the method of claim 31.

### Claim 33 (depends on 1)

The peptide of claim 1, wherein the peptide is amidated.

### Claim 34 (depends on 7)

The method of claim 7, wherein the peptide is amidated.

### Claim 35 (depends on 25)

The method of claim 25, wherein the peptide is amidated.

### Claim 36 (depends on 1)

The peptide of claim 1, wherein the peptide is carboxymethylated.

### Claim 37 (depends on 7)

The peptide of claim 7, wherein the peptide is carboxymethylated.

### Claim 38 (depends on 25)

The peptide of claim 25, wherein the peptide is carboxymethylated.
